Drug facts
MoleculeTicagrelor (Brilinta)
Generics already compete: 19 makers on the market. 36 A-rated products from 19 makers substitute at the counter.
Brilinta was first approved by the FDA on 07/20/2011 under NDA 022433; the application holder is Astrazeneca Pharmaceuticals LP.
The latest NADAC for TICAGRELOR 90 MG TABLET is $0.24 per unit (as of 10/28/2026).
Holder Astrazeneca Pharmaceuticals LPApplication NDA 022433Approved 07/20/2011
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
3,557days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved07/20/2011
Last patent07/27/2036
2012201620202024202820322036
- Latest patent
- 07/27/2036Brilinta Orange Book
02Competition
- Generics
- 19 generic makers Orange Book
- First generic approved
- 09/04/2018 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Ticagrelor profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.24 per unitTICAGRELOR 90 MG TABLET, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Astrazeneca Pharmaceuticals LP Orange Book
- Application
- NDA 022433 Orange Book
- First approved
- 07/20/2011 Orange Book
- Dosage forms
- tablet
- Routes
- oral
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.